FEMASYS INC

Quarterly Report for period ending 2023-09-30

Quarterly Report for period ending 2023-06-30

Annual Report for period ending 2022-12-31

Quarterly Report for period ending 2023-03-31

Annual Report for period ending 2022-12-31

Annual Report for period ending 2022-12-31

Quarterly Report for period ending 2022-09-30

Quarterly Report for period ending 2022-06-30

Quarterly Report for period ending 2022-03-31

Annual Report for period ending 2021-12-31

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Notice of Effectiveness

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

Exempt (Private) Offering

Notice of Effectiveness

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

Annual report to security holders

Notice of Effectiveness

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

Certification by an exchange approving securities for listing

Spector Richard D.: Initial statement of beneficial ownership of securities

Spector Richard D.: Statement of changes in beneficial ownership of securities

Currie Daniel Scott: Statement of changes in beneficial ownership of securities

Lee-Sepsick Kathy: Statement of changes in beneficial ownership of securities

Elefant Dov: Statement of changes in beneficial ownership of securities

Thomas Christine E: Statement of changes in beneficial ownership of securities

PharmaCyte Biotech, Inc.: Initial statement of beneficial ownership of securities

PharmaCyte Biotech, Inc.: Major Shareholders

Silverman Joshua: Statement of changes in beneficial ownership of securities

Silverman Joshua: Initial statement of beneficial ownership of securities

Prospectus filed pursuant to Rule 424(b)(3)

Registration statement for specified transactions by certain issuers

Prospectus filed pursuant to Rule 424(b)(3)

Prospectus filed pursuant to Rule 424(b)(3)

General form of registration statement for all companies including face-amount certificate companies

General form of registration statement for all companies including face-amount certificate companies

Prospectus filed pursuant to Rule 424(b)(3)

Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Prospectus filed pursuant to Rule 424(b)(3)

Prospectus filed pursuant to Rule 424(b)(3)

Definitive proxy statements

Preliminary proxy statement not related to a contested matter or merger/acquisition

Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.

Definitive proxy statements

Preliminary proxy statement not related to a contested matter or merger/acquisition

Definitive proxy statements

Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.